Structure of Tazemetostat
CAS No.: 1403254-99-8
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Tazemetostat (EPZ-6438) is a potent and selective inhibitor of EZH2, available orally. It inhibits the activity of the human polycomb repressive complex 2 (PRC2) containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat (EPZ-6438) inhibits EZH2 with IC50 values of 11 and 16 nM in peptide and nucleosome assays, respectively. It inhibits rat EZH2 with an IC50 of 4 nM. Additionally, Tazemetostat (EPZ-6438) inhibits EZH1 with an IC50 of 392 nM.
Synonyms: EPZ-6438; E7438; E-7438
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1403254-99-8 |
Formula : | C34H44N4O4 |
M.W : | 572.74 |
SMILES Code : | O=C(C1=CC(C2=CC=C(CN3CCOCC3)C=C2)=CC(N(CC)C4CCOCC4)=C1C)NCC5=C(C)C=C(C)NC5=O |
Synonyms : |
EPZ-6438; E7438; E-7438
|
MDL No. : | MFCD24849415 |
InChI Key : | NSQSAUGJQHDYNO-UHFFFAOYSA-N |
Pubchem ID : | 66558664 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Description |
Tazemetostat (EPZ-6438) is a potent, selective, and orally available EZH2 inhibitor. It inhibits human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM and inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat also inhibits rat EZH2 with an IC50 of 4 nM and inhibits EZH1 with an IC50 of 392 nM. It induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells [1].
|
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
pancreatic ductal epithelial cells | 1 μM | 48 h | To evaluate the regenerative capacity of Tazemetostat on pancreatic ductal epithelial cells, results showed that Tazemetostat restored the expression of β-cell-related genes and promoted insulin secretion. | PMC10757994 |
IDH1R132H and IDH1 wild-type mouse glioma cells | 5 µM | 48 h | Tazemetostat significantly reduced H3K27me3 levels in both IDH1R132H and wild-type cells and significantly increased H3K27ac levels. | PMC10854521 |
DLBCL cell lines (SUDHL-4, DB, SUDHL-6, WSU-DLCL2, SUDHL-10, Karpas 422) | 1 μM | 48 h | To evaluate the effect of Tazemetostat on HLA I and HLA-A*02 expression in DLBCL cell lines, results showed that Tazemetostat alone or in combination with Decitabine significantly upregulated HLA expression. | PMC9327544 |
EZH2 wild-type DLBCL cell lines (RI-1, U9-293) | 1 μM | 48 h | To evaluate the effect of Tazemetostat on HLA expression in EZH2 wild-type DLBCL cell lines, results showed that Tazemetostat had little to no effect on HLA expression in EZH2 wild-type cell lines. | PMC9327544 |
neural progenitor cells | 1 µM | 5 days | To evaluate the effect of EZH2 inhibition on cell proliferation, results showed that EZH2 inhibition accelerated cell proliferation. | PMC8994223 |
SUDHL-4 | 312.5-5000 nM | 48 h | Tazemetostat decreases global H3K27me3 with 96 h of drug treatment. | PMC9327544 |
DB | 312.5-5000 nM | 48 h | Tazemetostat upregulated HLA I and HLA-A*02 cell surface expression. | PMC9327544 |
SUDHL-6 | 312.5-5000 nM | 48 h | Tazemetostat upregulated HLA I and HLA-A*02 cell surface expression. | PMC9327544 |
MKL-1 | 3 μM | 6 and 12 days | To assess the transcriptional changes in MKL-1 cells treated with EPZ011989, observing upregulation of SIX1 and increased expression of its downstream gene MYO6 | PMC9492898 |
WaGa | 0.5 μM | 12 days | To assess the impact of Tazemetostat on WaGa cell viability, observing significant reduction in cell viability | PMC9492898 |
LNCaP cells | 1 μM | 5 days | Validating the synergistic antiproliferative effect of EPZ-6438 and enzalutamide | PMC6191320 |
C4-2B cells | 1 μM | 5 days | Screening EZH2 inhibitors to enhance the inhibitory effect of enzalutamide on cell proliferation | PMC6191320 |
LNCaP cells | 1 μM | 5 days | Validate the synergistic antiproliferative effects of EPZ-6438 and enzalutamide co-treatment. | PMC6191320 |
C4-2B cells | 1 μM | 5 days | Screening epigenetic inhibitors, EZH2 inhibitors significantly enhanced the inhibitory effect of enzalutamide on cell proliferation. | PMC6191320 |
TNBC cell lines | 5 μM | 5 days pretreatment followed by 4 days of combination treatment | To evaluate the cytotoxic effects of MAK683 in combination with AKT inhibitors on TNBC cells, showing that 60% of cell lines were highly sensitive to this combination, resulting in substantial cell depletion | PMC11578877 |
G401 cells | 10 μM | 11 days | Evaluate the effect of RB1 loss on TAZ resistance | PMC11147720 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
mice | H3K27M DMG tumor model | intraperitoneal | 400 mg/kg | once daily for 7 days | To evaluate the effect of Tazemetostat on tumor proliferation and survival, results showed that Tazemetostat did not significantly alter tumor proliferation or significantly impact survival. | PMC8994223 |
mice | xenograft model | oral | 0.5 mg/kg | twice a week for 3 weeks | The combination of tazemetostat and bortezomib significantly suppressed tumor growth and prolonged the survival of mice. | PMC8843744 |
NSG mice | Multiple myeloma model | Oral | 0.5 g/kg | Three times a week for 3 weeks | To evaluate the therapeutic efficacy of Tazemetostat in combination with Bortezomib in a multiple myeloma mouse model. | PMC8722039 |
NOD scid gamma mice | MKL-1 xenograft model | Oral | 400 mg/kg | Twice daily for 19 days | To assess the impact of Tazemetostat on MKL-1 xenograft growth, observing delayed tumor growth and induction of SIX1 and MYO6 expression | PMC9492898 |
NSG mice | Patient-derived xenograft model | Oral gavage and intraperitoneal injection | 250 mg/kg | Twice daily, 7 days per week | Evaluate the inhibitory effect of TAZ and barasertib combination on tumor growth | PMC11147720 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT05228158 | Lymphoma, Follicular | RECRUITING | 2028-03-31 | Eisai Trial Site 172, Anjo-shi... More >>, Aichi, Japan|Eisai Trial Site 129, Komaki-shi, Aichi, Japan|Eisai Trial Site 210, Konan-shi, Aichi, Japan|Eisai Trial Site 20, Nagakute-shi, Aichi, Japan|Eisai Trial Site 105, Nagoya-shi, Aichi, Japan|Eisai Trial Site 152, Nagoya-shi, Aichi, Japan|Eisai Trial Site 163, Nagoya-shi, Aichi, Japan|Eisai Trial Site 168, Nagoya-shi, Aichi, Japan|Eisai Trial Site 90, Nagoya-shi, Aichi, Japan|Eisai Trial Site 91, Nagoya-shi, Aichi, Japan|Eisai Trial Site 93, Nagoya-shi, Aichi, Japan|Eisai Trial Site 99, Nagoya-shi, Aichi, Japan|Eisai Trial Site 217, Obu-shi, Aichi, Japan|Eisai Trial Site 165, Okazaki-shi, Aichi, Japan|Eisai Trial Site 174, Okazaki-shi, Aichi, Japan|Eisai Trial Site 176, Seto-shi, Aichi, Japan|Eisai Trial Site 151, Toyoake-shi, Aichi, Japan|Eisai Trial Site 128, Toyohashi-shi, Aichi, Japan|Eisai Trial Site 238, Toyokawa-shi, Aichi, Japan|Eisai Trial Site 131, Toyota-shi, Aichi, Japan|Eisai Trial Site 216, Yatomi-shi, Aichi, Japan|Eisai Trial Site 167, Akita-shi, Akita, Japan|Eisai Trial Site 94, Aomori-shi, Aomori, Japan|Eisai Trial Site 95, Hirosaki-shi, Aomori, Japan|Eisai Trial Site 118, Chiba-shi, Chiba, Japan|Eisai Trial Site 50, Chiba-shi, Chiba, Japan|Eisai Trial Site 79, Chiba-shi, Chiba, Japan|Eisai Trial Site 115, Kamogawa-shi, Chiba, Japan|Eisai Trial Site 4, Kashiwa-shi, Chiba, Japan|Eisai Trial Site 83, Kashiwa-shi, Chiba, Japan|Eisai Trial Site 206, Matsudo-shi, Chiba, Japan|Eisai Trial Site 38, Matsudo-shi, Chiba, Japan|Eisai Trial Site 103, Narita-shi, Chiba, Japan|Eisai Trial Site 109, Urayasu-shi, Chiba, Japan|Eisai Trial Site 24, Matsuyama-shi, Ehime, Japan|Eisai Trial Site 68, Fukui-shi, Fukui, Japan|Eisai Trial Site 66, Yoshida-gun, Fukui, Japan|Eisai Trial Site 14, Fukuoka-shi, Fukuoka, Japan|Eisai Trial Site 186, Fukuoka-shi, Fukuoka, Japan|Eisai Trial Site 18, Fukuoka-shi, Fukuoka, Japan|Eisai Trial Site 240, Fukuoka-shi, Fukuoka, Japan|Eisai Trial Site 45, Fukuoka-shi, Fukuoka, Japan|Eisai Trial Site 132, Iizuka-shi, Fukuoka, Japan|Eisai Trial Site 114, Kitakyushu-shi, Fukuoka, Japan|Eisai Trial Site 119, Kitakyushu-shi, Fukuoka, Japan|Eisai Trial Site 134, Kitakyushu-shi, Fukuoka, Japan|Eisai Trial Site 243, Kitakyusyu-shi, Fukuoka, Japan|Eisai Trial Site 245, Kurume-shi, Fukuoka, Japan|Eisai Trial Site 113, Iwaki-shi, Fukushima, Japan|Eisai Trial Site 81, Iwaki-shi, Fukushima, Japan|Eisai Trial Site 184, Shirakawa-shi, Fukushima, Japan|Eisai Trial Site 26, Gifu-shi, Gifu, Japan|Eisai Trial Site 27, Gifu-shi, Gifu, Japan|Eisai Trial Site 180, Ogaki-shi, Gifu, Japan|Eisai Trial Site 236, Maebashi-shi, Gumma, Japan|Eisai Trial Site 44, Fujioka-shi, Gunma, Japan|Eisai Trial Site 145, Shibukawa-shi, Gunma, Japan|Eisai Trial Site 56, Fukuyama-shi, Hiroshima, Japan|Eisai Trial Site 36, Hiroshima-shi, Hiroshima, Japan|Eisai Trial Site 51, Hiroshima-shi, Hiroshima, Japan|Eisai Trial Site 9, Hiroshima-shi, Hiroshima, Japan|Eisai Trial Site 127, Asahikawa-shi, Hokkaido, Japan|Eisai Trial Site 234, Asahikawa-shi, Hokkaido, Japan|Eisai Trial Site 110, Hakodate-shi, Hokkaido, Japan|Eisai Trial Site 209, Kitami-shi, Hokkaido, Japan|Eisai Trial Site 70, Kushiro-shi, Hokkaido, Japan|Eisai Trial Site 7, Muroran-shi, Hokkaido, Japan|Eisai Trial Site 220, Obihiro-shi, Hokkaido, Japan|Eisai Trial Site 159, Sapporo-shi, Hokkaido, Japan|Eisai Trial Site 162, Sapporo-shi, Hokkaido, Japan|Eisai Trial Site 173, Sapporo-shi, Hokkaido, Japan|Eisai Trial Site 46, Sapporo-shi, Hokkaido, Japan|Eisai Trial Site 223, Akashi-shi, Hyogo, Japan|Eisai Trial Site 71, Akashi-shi, Hyogo, Japan|Eisai Trial Site 30, Amagasaki-shi, Hyogo, Japan|Eisai Trial Site 153, Himeji-shi, Hyogo, Japan|Eisai Trial Site 123, Itami-shi, Hyogo, Japan|Eisai Trial Site 207, Kobe-shi, Hyogo, Japan|Eisai Trial Site 84, Kobe-shi, Hyogo, Japan|Eisai Trial Site 88, Kobe-shi, Hyogo, Japan|Eisai Trial Site 92, Kobe-shi, Hyogo, Japan|Eisai Trial Site 43, Nishinomiya-shi, Hyogo, Japan|Eisai Trial Site 28, Hitachi-shi, Ibaraki, Japan|Eisai Trial Site 148, Ibaraki-gun, Ibaraki, Japan|Eisai Trial Site 142, Tsuchiura-shi, Ibaraki, Japan|Eisai Trial Site 10, Tsukuba-shi, Ibaraki, Japan|Eisai Trial Site 230, Tsukuba-shi, Ibaraki, Japan|Eisai Trial Site 166, Kanazawa-shi, Ishikawa, Japan|Eisai Trial Site 37, Kanazawa-shi, Ishikawa, Japan|Eisai Trial Site 116, Kita-gun, Kagawa, Japan|Eisai Trial Site 85, Sakaide-shi, Kagawa, Japan|Eisai Trial Site 104, Takamatsu-shi, Kagawa, Japan|Eisai Trial Site 111, Takamatsu-shi, Kagawa, Japan|Eisai Trial Site 117, Kagoshima-shi, Kagoshima, Japan|Eisai Trial Site 33, Kagoshima-shi, Kagoshima, Japan|Eisai Trial Site 218, Kanoya-shi, Kagoshima, Japan|Eisai Trial Site 108, Ebina-shi, Kanagawa, Japan|Eisai Trial Site 150, Kamakura-shi, Kanagawa, Japan|Eisai Trial Site 137, Kawasaki-shi, Kanagawa, Japan|Eisai Trial Site 16, Kawasaki-shi, Kanagawa, Japan|Eisai Trial Site 181, Kawasaki-shi, Kanagawa, Japan|Eisai Trial Site 86, Sagamihara-shi, Kanagawa, Japan|Eisai Trial Site 124, Yokohama-shi, Kanagawa, Japan|Eisai Trial Site 169, Yokohama-shi, Kanagawa, Japan|Eisai Trial Site 42, Yokohama-shi, Kanagawa, Japan|Eisai Trial Site 6, Yokohama-shi, Kanagawa, Japan|Eisai Trial Site 76, Yokohama-shi, Kanagawa, Japan|Eisai Trial Site 164, Yokosuka-shi, Kanagawa, Japan|Eisai Trial Site 8, Nankoku-shi, Kochi, Japan|Eisai Trial Site 175, Kumamoto-shi, Kumamoto, Japan|Eisai Trial Site 211, Kumamoto-shi, Kumamoto, Japan|Eisai Trial Site 54, Kumamoto-shi, Kumamoto, Japan|Eisai Trial Site 67, Kumamoto-shi, Kumamoto, Japan|Eisai Trial Site 53, Fukuchiyama-shi, Kyoto, Japan|Eisai Trial Site 12, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 133, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 25, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 3, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 55, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 75, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 98, Iga-shi, Mie, Japan|Eisai Trial Site 31, Ise-shi, Mie, Japan|Eisai Trial Site 121, Matsusaka-shi, Mie, Japan|Eisai Trial Site 35, Matsusaka-shi, Mie, Japan|Eisai Trial Site 107, Suzuka-shi, Mie, Japan|Eisai Trial Site 226, Suzuka-shi, Mie, Japan|Eisai Trial Site 186, Yokkaichi-shi, Mie, Japan|Eisai Trial Site 63, Natori-shi, Miyagi, Japan|Eisai Trial Site 157, Sendai-shi, Miyagi, Japan|Eisai Trial Site 73, Sendai-shi, Miyagi, Japan|Eisai Trial Site 179, Nobeoka-shi, Miyazaki, Japan|Eisai Trial Site 203, Matsumoto-shi, Nagano, Japan|Eisai Trial Site 219, Matsumoto-shi, Nagano, Japan|Eisai Trial Site 61, Nagano-shi, Nagano, Japan|Eisai Trial Site 125, Nagasaki-shi, Nagasaki, Japan|Eisai Trial Site 222, Omura-shi, Nagasaki, Japan|Eisai Trial Site 136, Tenri-shi, Nara, Japan|Eisai Trial Site 225, Joetsu-shi, Niigata, Japan|Eisai Trial Site 5, Kurashiki-shi, Okayama, Japan|Eisai Trial Site 2, Maniwa-shi, Okayama, Japan|Eisai Trial Site 11, Okayama-shi, Okayama, Japan|Eisai Trial Site 13, Okayama-shi, Okayama, Japan|Eisai Trial Site 170, Okayama-shi, Okayama, Japan|Eisai Trial Site 40, Okayama-shi, Okayama, Japan|Eisai Trial Site 41, Okayama-shi, Okayama, Japan|Eisai Trial Site 17, Nakagami-gun, Okinawa, Japan|Eisai Trial Site 215, Okinawa-shi, Okinawa, Japan|Eisai Trial Site 96, Uruma-shi, Okinawa, Japan|Eisai Trial Site 160, Hirakata-shi, Osaka, Japan|Eisai Trial Site 153, Izumi-shi, Osaka, Japan|Eisai Trial Site 48, Izumisano-shi, Osaka, Japan|Eisai Trial Site 58, Kawachinagano-shi, Osaka, Japan|Eisai Trial Site 65, Moriguchi-shi, Osaka, Japan|Eisai Trial Site 112, Osaka-shi, Osaka, Japan|Eisai Trial Site 122, Osaka-shi, Osaka, Japan|Eisai Trial Site 141, Osaka-shi, Osaka, Japan|Eisai Trial Site 147, Osaka-shi, Osaka, Japan|Eisai Trial Site 161, Osaka-shi, Osaka, Japan|Eisai Trial Site 171, Osaka-shi, Osaka, Japan|Eisai Trial Site 183, Osaka-shi, Osaka, Japan|Eisai Trial Site 221, Osaka-shi, Osaka, Japan|Eisai Trial Site 224, Osaka-shi, Osaka, Japan|Eisai Trial Site 231, Osaka-shi, Osaka, Japan|Eisai Trial Site 232, Osaka-shi, Osaka, Japan|Eisai Trial Site 241, Osaka-shi, Osaka, Japan|Eisai Trial Site 29, Osaka-shi, Osaka, Japan|Eisai Trial Site 52, Osaka-shi, Osaka, Japan|Eisai Trial Site 59, Osaka-shi, Osaka, Japan|Eisai Trial Site 21, Osakasayama-shi, Osaka, Japan|Eisai Trial Site 233, Sakai-shi, Osaka, Japan|Eisai Trial Site 130, Suita-shi, Osaka, Japan|Eisai Trial Site 246, Takatsuki-shi, Osaka, Japan|Eisai Trial Site 60, Takatsuki-shi, Osaka, Japan|Eisai Trial Site 97, Toyonaka-shi, Osaka, Japan|Eisai Trial Site 144, Hidaka-shi, Saitama, Japan|Eisai Trial Site 140, Iruma-gun, Saitama, Japan|Eisai Trial Site 173, Kawagoe-shi, Saitama, Japan|Eisai Trial Site 74, Koshigaya-shi, Saitama, Japan|Eisai Trial Site 148, Saitama-shi, Saitama, Japan|Eisai Trial Site 208, Saitama-shi, Saitama, Japan|Eisai Trial Site 138, Tokorozawa-shi, Saitama, Japan|Eisai Trial Site 229, Nagahama-shi, Shiga, Japan|Eisai Trial Site 177, Otsu-shi, Shiga, Japan|Eisai Trial Site 227, Otsu-shi, Shiga, Japan|Eisai Trial Site 102, Ritto-shi, Shiga, Japan|Eisai Trial Site 235, Iwata-shi, Shizuoka, Japan|Eisai Trial Site 39, Izunokuni-shi, Shizuoka, Japan|Eisai Trial Site 143, Shimada-shi, Shizuoka, Japan|Eisai Trial Site 205, Shizuoka-shi, Shizuoka, Japan|Eisai Trial Site 87, Shizuoka-shi, Shizuoka, Japan|Eisai Trial Site 22, Sunto-gun, Shizuoka, Japan|Eisai Trial Site 34, Shimotsuga-gun, Tochigi, Japan|Eisai Trial Site 212, Shimotsuke-shi, Tochigi, Japan|Eisai Trial Site 100, Tokushima-shi, Tokushima, Japan|Eisai Trial Site 182, Tokushima-shi, Tokushima, Japan|Eisai Trial Site 64, Tokushima-shi, Tokushima, Japan|Eisai Trial Site 154, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 204, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 72, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 77, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 237, Chiyoda-ku, Tokyo, Japan|Eisai Trial Site 1, Chuo-ku, Tokyo, Japan|Eisai Trial Site 106, Edogawa-ku, Tokyo, Japan|Eisai Trial Site 78, Itabashi-ku, Tokyo, Japan|Eisai Trial Site 120, Komae-shi, Tokyo, Japan|Eisai Trial Site 32, Koto-ku, Tokyo, Japan|Eisai Trial Site 242, Meguro-ku, Tokyo, Japan|Eisai Trial Site 146, Minato-ku, Tokyo, Japan|Eisai Trial Site 15, Minato-ku, Tokyo, Japan|Eisai Trial Site 49, Minato-ku, Tokyo, Japan|Eisai Trial Site 126, Mitaka-shi, Tokyo, Japan|Eisai Trial Site 89, Musashino-shi, Tokyo, Japan|Eisai Trial Site 135, Ome-shi, Tokyo, Japan|Eisai Trial Site 191, Ota-ku, Tokyo, Japan|Eisai Trial Site 149, Shinagawa-Ku, Tokyo, Japan|Eisai Trial Site 23, Shinagawa-Ku, Tokyo, Japan|Eisai Trial Site 158, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site 80, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site 155, Suginami-ku, Tokyo, Japan|Eisai Trial Site 156, Suginami-ku, Tokyo, Japan|Eisai Trial Site 244, Taito-ku, Tokyo, Japan|Eisai Trial Site 213, Toshima-ku, Tokyo, Japan|Eisai Trial Site 82, Yonago-shi, Tottori, Japan|Eisai Trial Site 101, Toyama-shi, Toyama, Japan|Eisai Trial Site 199, Toyama-shi, Toyama, Japan|Eisai Trial Site 57, Toyama-shi, Toyama, Japan|Eisai Trial Site 139, Tanabe-shi, Wakayama, Japan|Eisai Trial Site 47, Wakayama-shi, Wakayama, Japan|Eisai Trial Site 69, Wakayama-shi, Wakayama, Japan|Eisai Trial Site 19, Sakata-shi, Yamagata, Japan|Eisai Trial Site 62, Yamagata-shi, Yamagata, Japan|Eisai Trial Site 214, Ube-shi, Yamaguchi, Japan Less << | |
NCT03213665 | Advanced Malignant Solid Neopl... More >>asm|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Low Grade Glioma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Hodgkin Lymphoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Refractory Hodgkin Lymphoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Soft Tissue Sarcoma|Rhabdoid Tumor|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Wilms Tumor Less << | PHASE2 | COMPLETED | 2024-12-31 | Children's Hospital of Alabama... More >>, Birmingham, Alabama, 35233, United States|Providence Alaska Medical Center, Anchorage, Alaska, 99508, United States|Banner Children's at Desert, Mesa, Arizona, 85202, United States|Phoenix Childrens Hospital, Phoenix, Arizona, 85016, United States|Banner University Medical Center - Tucson, Tucson, Arizona, 85719, United States|Arkansas Children's Hospital, Little Rock, Arkansas, 72202-3591, United States|Kaiser Permanente Downey Medical Center, Downey, California, 90242, United States|Loma Linda University Medical Center, Loma Linda, California, 92354, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, 90806, United States|Children's Hospital Los Angeles, Los Angeles, California, 90027, United States|Mattel Children's Hospital UCLA, Los Angeles, California, 90095, United States|Valley Children's Hospital, Madera, California, 93636, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, 94609, United States|Kaiser Permanente-Oakland, Oakland, California, 94611, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, 94304, United States|Rady Children's Hospital - San Diego, San Diego, California, 92123, United States|UCSF Medical Center-Mission Bay, San Francisco, California, 94158, United States|Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, 80218, United States|Yale University, New Haven, Connecticut, 06520, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, 19803, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, 32610, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, 33021, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, 32207, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, 33136, United States|Nicklaus Children's Hospital, Miami, Florida, 33155, United States|AdventHealth Orlando, Orlando, Florida, 32803, United States|Arnold Palmer Hospital for Children, Orlando, Florida, 32806, United States|Nemours Children's Hospital, Orlando, Florida, 32827, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, 32504, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, 33701, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, 33607, United States|Saint Mary's Hospital, West Palm Beach, Florida, 33407, United States|Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, 30329, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, 96826, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, 83712, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, 61637, United States|Southern Illinois University School of Medicine, Springfield, Illinois, 62702, United States|Riley Hospital for Children, Indianapolis, Indiana, 46202, United States|Ascension Saint Vincent Indianapolis Hospital, Indianapolis, Indiana, 46260, United States|Blank Children's Hospital, Des Moines, Iowa, 50309, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242, United States|Norton Children's Hospital, Louisville, Kentucky, 40202, United States|Children's Hospital New Orleans, New Orleans, Louisiana, 70118, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, 70121, United States|Maine Children's Cancer Program, Scarborough, Maine, 04074, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, 21215, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, 48109, United States|Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, 49503, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, 49007, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, 55404, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, 55455, United States|University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, 64108, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, 63104, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, 63141, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, 68114, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, 89102, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, 89135, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Morristown Medical Center, Morristown, New Jersey, 07960, United States|Albany Medical Center, Albany, New York, 12208, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, 11040, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, 10016, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|NYP/Weill Cornell Medical Center, New York, New York, 10065, United States|University of Rochester, Rochester, New York, 14642, United States|State University of New York Upstate Medical University, Syracuse, New York, 13210, United States|New York Medical College, Valhalla, New York, 10595, United States|Mission Hospital, Asheville, North Carolina, 28801, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, 28203, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|Dayton Children's Hospital, Dayton, Ohio, 45404, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, 43606, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, 97227, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|Geisinger Medical Center, Danville, Pennsylvania, 17822, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, 15224, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, 29605, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, 57117-5134, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, 37916, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, 37232, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, 78723, United States|Medical City Dallas Hospital, Dallas, Texas, 75230, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Cook Children's Medical Center, Fort Worth, Texas, 76104, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, 77030, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Children's Hospital of San Antonio, San Antonio, Texas, 78207, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, 78229, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States|Scott and White Memorial Hospital, Temple, Texas, 76508, United States|Primary Children's Hospital, Salt Lake City, Utah, 84113, United States|University of Vermont and State Agricultural College, Burlington, Vermont, 05405, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, 23507, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, 23298, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, 99204, United States|Madigan Army Medical Center, Tacoma, Washington, 98431, United States|West Virginia University Healthcare, Morgantown, West Virginia, 26506, United States|University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, 53792, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, 53226, United States|San Jorge Children's Hospital, San Juan, 00912, Puerto Rico|University Pediatric Hospital, San Juan, 00926, Puerto Rico Less << |
NCT04225429 | Epithelioid Sarcoma | NO_LONGER_AVAILABLE | - | - | |
NCT04241835 | Hepatic Impairment|Advanced Ma... More >>lignant Solid Tumor Less << | PHASE1 | RECRUITING | 2025-06-17 | Florida Cancer Specialists & R... More >>esearch Institute, Lake Mary, Florida, 32746, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, 60611, United States|Hematology Oncology Consultants, Royal Oak, Michigan, 48073, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, 89014, United States|Rutgers Cancer Institute, New Brunswick, New Jersey, 08901, United States|Gabrail Cancer Center, Canton, Ohio, 44718, United States|Mary Crowley Cancer Research, Dallas, Texas, 75230, United States|Oncology Consultants - Texas Medical Center, Houston, Texas, 77030, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|Antwerp University Hospital, Edegem, Antwerp, 2650, Belgium|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|Institut Bergonie, Bordeaux Cedex, 33076, France|Centre Oscar Lambret, Lille, 59020, France|Hopital de la Timone, Marseille, 13005, France|Institut de Cancérologie Strasbourg Europe, Strasbourg, France|Biokinetica S.A Przychodnia Jozefow, Józefów, Mazowieckie, 05410, Poland|MedPolonia, Poznań, Wielkopolskie, 60693, Poland|Summit Clinical Research, s.r.o, Bratislava, 831 01, Slovakia Less << |
NCT02875548 | Diffuse Large B-cell Lymphoma ... More >>(DLBCL)|Follicular Lymphoma (FL)|Synovial Sarcoma|Epitheliod Sarcoma (ES)|Mesothelioma|Advanced Solid Tumors|Renal Medullary Carcinoma|Non-Hodgkin Lymphoma (NHL) Less << | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | 2025-11-03 | University of Arizona Cancer C... More >>enter, Tucson, Arizona, 85724, United States|California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, 92024, United States|Hematology Oncology Associates of the Treasure Coast - Port St. Lucie, Port Saint Lucie, Florida, 34952, United States|Moffitt, Tampa, Florida, 33612, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Central Care Cancer Center, Bolivar, Missouri, 65613, United States|Astera Cancer Center, East Brunswick, New Jersey, 08816, United States|Columbia University Medical Center, New York, New York, 10019, United States|David H. Koch Center for Cancer Care at memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Princess Alexandra Hospital, Alexandra, Australia|Monash Medical Centre- Monash Campus, Clayton, 3168, Australia|Geelong Hospital, Geelong, Australia|Peter MacCallum Cancer Institute, Melbourne, 3002, Australia|Monash Health, Monash, Australia|University Hospital (UZ) Leuven, Leuven, 3000, Belgium|Institut Bergonie, Bordeaux Cedex, 33076, France|CHU de Caen - H?pital C?te de Nacre, Caen, 14033, France|CHRU de Lile- Hopital Claude Huriez, Lille Cedex, 59037, France|CHU de Montpellier - Hopital Saint Eloi, Montpellier, France|H?pital Saint Louis - AP-HP, Paris, 75010, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, 69310, France|CHU Rennes- Hopital Pontchaillou, Rennes Cedex, 35033, France|Centre Henri Becquerel, Rouen, 76038, France|Gustave Roussay, Villejuif, 94805, France|Pratia MCM Krakow, Kraków, 30-510, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Endokrynologii Onkologicznej i Medycyny Nuklearnej, Warszawa, Poland|S.P. Grigoreva Institute of Medical Radiology and Oncology of NAMS of Ukraine", Kharkiv, 61024, Ukraine|Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom|Oncology and Haematology Clinical Trials Unit, Leicester, LEI 5WW, United Kingdom|Clatterbridge Cancer Centre, Liverpool, L7 8XP, United Kingdom|Hammersmith Hospital, London, W12 0HS, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom Less << |
NCT02860286 | Mesothelioma|BAP1 Loss of Func... More >>tion Less << | PHASE2 | COMPLETED | 2025-05-19 | University of California, Los ... More >>Angeles, Los Angeles, California, 90025, United States|City of Hope National Medical Center, Los Angeles, California, 90301, United States|University of California San Francisco, San Francisco, California, 94143, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mayo Clinic - Rochester, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Institut Bergonie, Bordeaux Cedex, 33076, France|CHRU de Lille, Lille, 59037, France|Institut Gustave Roussy, Villejuif cedex, 94805, France|University of Leicester & Leicester University Hospitals, Leicester, LE1 9HN, United Kingdom|St. Bartholomew's Hospital, London, EC1M 6BQ, United Kingdom|University College Hospital, London, NW1 2PG, United Kingdom|Royal Marsden Hospital - Chelsea, London, SW3 6JJ, United Kingdom|University Hospital of South Manchester, Manchester, M23 9LT, United Kingdom|Royal Marsden Hospital - Surrey, Sutton, SM2 5PT, United Kingdom Less << |
NCT05467943 | Relapsed/Refractory Follicular... More >> Lymphoma With EZH2 Less << | PHASE2 | COMPLETED | 2024-11-30 | Shanghai Cancer Center, Shangh... More >>ai, Shanghai, 200032, China Less << |
NCT03456726 | Relapsed or Refractory B-cell ... More >>Non-Hodgkin's Lymphoma Less << | PHASE2 | COMPLETED | 2021-12-17 | 1004 Eisai Trial Site, Nagoya,... More >> Aichi, Japan|1029 Eisai Trial Site, Nagoya, Aichi, Japan|1020 Eisai Trial Site, Ota, Gunma, Japan|1007 Eisai Trial Site, Sapporo, Hokkaido, Japan|1019 Eisai Trial Site, Kobe, Hyogo, Japan|1005 Eisai Trial Site, Tsukuba, Ibaraki, Japan|1002 Eisai Trial Site, Isehara, Kanagawa, Japan|1028 Eisai Trial Site, Yokohama, Kanagawa, Japan|1021 Eisai Trial Site, Sendai, Miyagi, Japan|1013 Eisai Trial Site, Osakasayama, Osaka, Japan|1006 Eisai Trial Site, Suita, Osaka, Japan|1027 Eisai Trial Site, Suntou-gun, Shizuoka, Japan|1026 Eisai Trial Site, Bunkyo-ku, Tokyo, Japan|1001 Eisai Trial Site, Chuo-ku, Tokyo, Japan|1025 Eisai Trial Site, Koto-ku, Tokyo, Japan|1017 Eisai Trial Site, Minato-ku, Tokyo, Japan|1022 Eisai Trial Site, Aomori, Japan|1010 Eisai Trial Site, Chiba, Japan|1012 Eisai Trial Site, Fukuoka, Japan|1016 Eisai Trial Site, Fukuoka, Japan|1011 Eisai Trial Site, Hiroshima, Japan|1024 Eisai Trial Site, Kumamoto, Japan|1003 Eisai Trial Site, Kyoto, Japan|1008 Eisai Trial Site, Kyoto, Japan|1023 Eisai Trial Site, Nagasaki, Japan|1009 Eisai Trial Site, Okayama, Japan|1015 Eisai Trial Site, Osaka, Japan|1018 Eisai Trial Site, Yamagata, Japan Less << |
NCT03009344 | Relapsed or Refractory B-cell ... More >>Non-Hodgkin's Lymphoma Less << | PHASE1 | COMPLETED | 2020-06-17 | Eisai Trial Site, Isehara, Kan... More >>agawa, Japan|Eisai Trial Site, Chuo-ku, Tokyo, Japan Less << |
NCT03874455 | Epithelioid Sarcoma (Ex-US Onl... More >>y)|Spindle Cell Sarcoma|Sinonasal Carcinoma|Small Cell Carcinoma of the Ovary Hypercalcemic Type|Thoracic Sarcoma|Poorly Differentiated Chordoma|ATRT|Malignant Rhabdoid Tumor of Kidney|Malignant Rhabdoid Tumor of Ovary|Malignant Rhabdoid Tumor|Myxoid Spindle Cell Sarcoma|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Chondrosarcoma|Renal Cell Carcinoma|Myoepithelial Carcinoma|Synovial Sarcoma|Renal Medullary Carcinoma|Malignant Mesothelioma|Desmoplastic Small Round Cell Tumor (DSRCT)|Intramedullary Spinal Cord Schwannomatosis Less << | NO_LONGER_AVAILABLE | - | - | |
NCT05983965 | T-cell Lymphoma | PHASE1 | RECRUITING | 2025-12-29 | University of Alabama at Birmi... More >>ngham, Birmingham, Alabama, 35294, United States Less << |
NCT04917042 | Peripheral Nerve Sheath Tumor | PHASE2 | RECRUITING | 2025-09-25 | University of Florida, Gainesv... More >>ille, Florida, 32608, United States Less << |
NCT05023655 | Solid Tumor|ARID1A Gene Mutati... More >>on Less << | PHASE2 | RECRUITING | 2025-01-27 | Prisma Health Cancer Institute... More >>, Greenville, South Carolina, 29605, United States Less << |
NCT02601950 | Malignant Rhabdoid Tumors (MRT... More >>)|Rhabdoid Tumors of the Kidney (RTK)|Atypical Teratoid Rhabdoid Tumors (ATRT)|Selected Tumors With Rhabdoid Features|Synovial Sarcoma|INI1-negative Tumors|Malignant Rhabdoid Tumor of Ovary|Renal Medullary Carcinoma|Epithelioid Sarcoma|Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)|Any Solid Tumor With an EZH2 GOF Mutation Less << | PHASE2 | COMPLETED | 2024-02-26 | University of California San F... More >>rancisco, San Francisco, California, 94115, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, 32224, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|Massachusetts General Hospital - Cancer Center, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Washington University, Saint Louis, Missouri, 63130, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Oregon Health Sciences University, Portland, Oregon, 97239, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Metro South Hospital and Health Service via Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia|Institut Jules Bordet Medical Oncology Clinic, Brussels, 1000, Belgium|University Hospital Leuven, Leuven, 3000, Belgium|Alberta Health Services, Edmonton, Alberta, T6G 1Z2, Canada|Princess Margaret Hospital, Toronto, Ontario, M5G 1X8, Canada|McGill University Health Centre - Royal Victoria Hospital, Montreal, Quebec, H4A 3J1, Canada|Institut Bergonie, Bordeaux, 33076, France|Centre Leon Berard, Lyon, 69008, France|Hospital Pitie Salpetriere, Paris Cedex 13, 75651, France|Institut Curie, Paris, 75248, France|Institut Gustave Roussy, Villejuif, 94800, France|Children's Hospital Augsburg Klinikum, Augsburg, 86156, Germany|Sarcoma Center HELIOS Klinikum Berlin, Berlin, 13125, Germany|Instituto Nazionale Tumori - National Cancer Institute Via Giacomo Venezian, Milano, 20133, Italy|National Taiwan University Hospital, Taipei City, 10002, Taiwan|University College London Hospital, London, NW1 2PG, United Kingdom|Royal Marsden Foundation Trust, London, SW3 6JJ, United Kingdom Less << |
NCT05018975 | COVID-19 Acute Respiratory Dis... More >>tress Syndrome|Cytokine Release Syndrome Less << | PHASE2 | WITHDRAWN | 2023-09-21 | - |
NCT02601937 | Rhabdoid Tumors|INI1-negative ... More >>Tumors|Synovial Sarcoma|Malignant Rhabdoid Tumor of Ovary Less << | PHASE1 | COMPLETED | 2021-10-22 | Children's Hospital of Los Ang... More >>eles, Los Angeles, California, 90027, United States|University of California San Francisco - Benioff Children's Hospital, San Francisco, California, 94158, United States|Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, 30322, United States|Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|John Hopkins Kimmel Cancer Center, Baltimore, Maryland, 21287, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Massachusetts General Hospital - Cancer Center, Boston, Massachusetts, 02215, United States|Memorial Sloan Kettering, New York, New York, 10065, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Oregon Health & Science University (OHSU), Portland, Oregon, 97239, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|St. Jude Children's Research Hospital, Inc., Memphis, Tennessee, 38105, United States|UT Southwestern Medical Center, Dallas, Texas, 75235, United States|Texas Children's Cancer and Hematology Center, Houston, Texas, 77098, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Sydney Children's Hospital, Sydney, New South Wales, 2031, Australia|Lady Cilento/Queensland Children's Hospital, South Brisbane, Queensland, 4101, Australia|The Royal Children's Hospital, Melbourne, Victoria, 3052, Australia|The Childrens Hospital at Westmead Oncology Unit, Westmead, 2145, Australia|The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada|Rigshospitalet Department of Oncology Blegdamsvej, Copenhagen, 2100, Denmark|Institut Curie, Paris, 75248, France|Institut Gustave Roussy, Villejuif, 94800, France|Children's Hospital Augsburg Klinikum, Augsburg, 86156, Germany|Charite - Universitatsmedizin Berlin, Berlin, 13353, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Westfalische Wilhelms - Universitat Munster Padiatrische, Munster, 48149, Germany|Istituto Giannina Gaslini- UOSD Centro di Neuro-Oncologia, Genova, 16147, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy|Erasmus University Medical Center - Sophia Children's Hospital, Rotterdam, Netherlands|Prinses Maxima Centrum voor Kinderoncologie, Utrecht, 3584 EA, Netherlands|Great Ormond Street Hospital for Children NHS Foundation Trust, London, WC1N 3JH, United Kingdom|Central Manchester University Hospital - Royal Manchester Children's Hospital, Manchester, M13 9WL, United Kingdom Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.75mL 0.35mL 0.17mL |
8.73mL 1.75mL 0.87mL |
17.46mL 3.49mL 1.75mL |